Our laboratory is testing the hypothesis that hypomethylation of DNA [a decreased content of 5-methylcytosine (5MeC) compared with cytosine] facilitates aberrant oncogene expression involved in tumorigenesis, using a model system of mouse strains with differing susceptibilities to liver tumorigenesis. The B6C3F1 (C57BL/6 x C3H/He) mouse serves as the relatively susceptible strain and C57BL/ 6 serves as the relatively resistant strain. Phenobarbital (PB) and/or administration of a choline-devoid, methioninedeficient diet (CMD) were employed as non-genotoxic hepatocarcinogens. We have examined hepatocyte and nonhepatocyte proliferation in conjunction with an assessment of global methylation changes in liver DNA of B6C3F1 and C57BL/6 mice following these promoter treatments. Bromodeoxyuridine incorporation into DNA, used to measure cell proliferation indirectly, was visualized by immunohistochemistry and quantified by a Macintosh-based image analysis system. Increased hepatocyte proliferation was demonstrated following all three treatments. This increase was larger in C57BL/6 (the relatively resistant strain) as compared with B6C3F1. In contrast, global hypomethylation was evident to a larger extent in the B6C3F1 mouse, as compared with C57BL/6. PB led to hypomethylation (>20% decrease as compared with controls) at weeks 1, 2 and 4 in B6C3F1, but not in C57BL/6 at the same time points. CMD diet administration led to hypomethylation in both strains. At week 1, 21 and 9% decreases in global methylation status were observed in B6C3F1 and C57BL/ 6 respectively. Evaluation of these data suggests that the heightened sensitivity of the B6C3F1 mouse compared with the C57BL/6 is due, in part, to a decreased capacity for, or fidelity of, maintaining normal methylation status. The relatively resistant strain is better able to maintain the normal methylation status of DNA in the face of a higher level of cell proliferation.
Introduction
5-Methylcytosine (5MeC*) is a naturally occurring methylated base in mammalian DNA that base pairs with guanine and is
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under-represented in the bulk of the genome, while it is commonly found in the promoter region of many genes (1). 5MeC content in DNA is, generally, inversely associated with gene expression. DNA methylation plays a role in regulating development and imprinting (2) . The mannose 6-phosphate/ insulin growth factor II receptor (M6P-IGF2r) is an imprinted gene where methylation has more than one function. In this gene the imprinting signal is methylation at a CpG site in an intron of the expressed allele, while the 5' flanking region must be hypomethylated for expression of the gene to occur (3) . Higher levels of gene expression may lead to perturbed cell growth and/or differentiation. However, if the gene is a tumor suppressor gene, hypermethylation would be anticipated to silence its expression and thus remove its essential function (4, 5) . Alterations in methylation may play a variety of roles in carcinogenesis (6) and we have emphasized testing the hypothesis that hypomethylation of DNA (a decreased level of 5MeC) facilitates aberrant gene expression involved in tumor promotion (7) . 5MeC is not incorporated directly into DNA, rather the methyl group is added to cytosine of the newly synthesized strand, at hemimethylated sites, after DNA replication through an Sadenosylmethionine (SAM)-requiring maintenance methylase (8) . Thus hypomethylation may occur secondary to increased cell proliferation if DNA maintenance methylation is not carried out faithfully (2, 7) . Additionally, de novo methylation (i.e. methylation not requiring a hemimethylated site) and demethylation not linked to DNA replication have been demonstrated and may play an important role in modifying DNA methylation status (2) . Cell proliferation is involved with many aspects of carcinogenesis (9) . It is required to fix a promutagenic lesion (10) and also to expand initiated cell populations through promotion and progression to a frank malignancy. Heightened cell proliferation may also facilitate mutagenesis (11). Thus cell proliferation can be involved in genetic and epigenetic aspects of tumorigenesis, by facilitating increased mutation rates and resulting in hypomethylation if the maintenance methylation reaction is not completed, i.e. all hemimethylated sites are not converted to fully methylated sites.
Choline and methionine are dietary sources providing methyl groups for the synthesis of SAM, the co-factor for methylation reactions. Diets devoid of choline and deficient in methionine (CMD diets) lead to increased hepatocyte cell proliferation (12, 13) , hypomethylation and increased expression of oncogenes (referenced in 14). Further, CMD diets lead to liver tumor formation in rats (15, 16) and choline-deficient diets are tumorigenic to B6C3F1 mice (17) . It has been demonstrated that the CMD diet leads to liver tumors primarily through promoting effects of the diet (18) . CMD diet administration for 12 months did not increase liver tumor formation in C3H/ HeN mice (19) . However, it should be noted that this time period would be too early to discern a CMD diet-induced increase in rat liver tumors (15) . The observation is of interest, however, as both B6C3F1 and C3H/He mice are considered to be relatively sensitive to liver tumor formation and exhibit a 100% liver tumor incidence after 12 months of phenobarbital (PB) administration (20) . Thus a CMD diet may promote liver tumor formation in a manner that is not precisely the same as PB administration. A role for methyl group deficiency as an epigenetic, non-genotoxic mechanism of tumorigenesis has been supported by the ability of excess choline and methionine to protect against aflatoxin-induced liver tumor formation in the B6C3F1 mouse (21) . Additionally, diets providing exogenous SAM have been demonstrated to protect against carcinogen-induced rat liver tumor formation (22) . These data support the hypothesis that hypomethylation of DNA is involved in tumor promotion (7) .
PB is a non-genotoxic rodent liver tumor promoter (23,24) which causes a transient increase in cell proliferation during the early times (i.e. 1-2 weeks) following its administration at a promoting dose (25) . There have been a few reports detailing the effects of co-administration of a choline-devoid diet and PB in the rat (13, 26, 27) . PB administered with a choline-devoid diet had a synergistic effect on the number and size of y-glutamyl transpeptidase (GGT)-positive foci, a putative marker of preneoplastic cells (26) .
We have examined cell proliferation and global hepatic methylation status in relatively liver tumor susceptible B6C3F1 mice and made relevant comparisons with relatively resistant C57BL/6 mice (20) following exposure to tumor promoting treatments, PB and/or a CMD diet. Cell proliferation was higher in C57BL/6, while hypomethylation occurred to a greater extent in B6C3F1. The dual administration of the CMD diet with PB led to enhanced cell proliferation and greater global hypomethylation, with similar trends in terms of strain sensitivities as compared with either treatment alone (i.e. greater increases in cell proliferation in C57BL/6 and greater levels of hypomethylation in B6C3F1). Thus B6C3F1 has a relatively low capacity to maintain the nascent methylation status of its hepatic DNA.
Materials and methods

Animals
Male B6C3F1 and C57BL/6 mice were obtained from Charles River (Portage, MI) and housed individually in a temperature and humidity controlled room on a 12 h light/dark schedule with food and water ad libitum. Animals were treated in accordance with applicable guidelines. The mice were acclimated to their surroundings for 1 week prior to being randomly assigned to a treatment group (six animals of each strain per group). All diets were purchased from Teklad (Madison, WI). The first group of animals received control diet [amino acid defined (TD 92106) with mineral mix, AIN-76 and vitamin mix (TD 40060)]. The second treatment consisted of a CMD diet [(TD 92107) with mineral mix, AIN-76 and vitamin mix (TD 83171)] containing the methionine precursor DL-homocystine (0.9% w/w) (15) . The third treatment was a liver tumor promoting dose of PB in the drinking water (0.05% w/w) (28) with control diet. The fourth treatment was co-administration of the CMD diet and PB. Animals were maintained in these groups for 1, 2 or 4 weeks. A 6 week time point recovery group, i.e. 4 weeks of treatment followed by 2 weeks of control diet, was included to examine reversibility. One week prior to sacrifice by CO2 asphyxiation animals were implanted s.c. with an osmotic minipump (Model 2002; Alza Corp.) containing 20 mg/ml bromodeoxyuridine (BrdU). Additionally, groups of male B6C3F1 and C57BL/6 mice received either control diet (TD 92106, AIN-76 and TD 40060) or CMD diet (TD 92107, AIN-76 and TD 83171) for 12 weeks. Animals were sacrificed by CO 2 asphyxiation, livers quickly excised, weighed, examined grossly, sections cut for histology and fixed. The remainder of the liver was snap frozen in liquid nitrogen until DNA isolation. Two B6C3F1 mice in the CMD diet + PB group and one C57BL/6 in the control diet + PB died prior to completion of the study; they were not included in any of the analyses. Further, minipumps dislodged from two animals and they were not included in the assessment of cell proliferation.
DNA isolation
DNA was isolated essentially as described (29) , with the addition of digestion with 400 Hg/ml RNase A (Sigma, St Louis, MO) and a second digestion with 200 Hg/ml proteinase K (Boehringer Mannheim Biochemicals, Indianapolis, IN).
Cell proliferation assessment
Immunohistochemical staining for BrdU incorporated into DNA was carried out utilizing anti-BrdU as the primary antibody and mouse anti-IgG as the secondary antibody. The detection system consisted of alkaline phosphatase utilizing Fast red as the chromagen (Biomeda Corp., Foster City, CA). Sections were lightly counterstained with hematoxylin prior to being mounted with Crystal Mount (Biomeda Corp.). With sections stained in this manner nuclei containing BrdU incorporated into DNA were stained red and the other nuclei were stained light blue.
A Sony DXC-960MD RGF camera attached to a Nikon microscope presented the light microscopic images to a Sony video monitor (model PVM I943MD) connected to a Power Macintosh 8I00/80AV computer equipped with a Scion LG3 frame grabber card (Scion, Frederick, MD). A two-monitor system was employed such that the live image could readily be compared with the digitized computer image. The NIH Image program (version 1.56) (public domain software written by Wayne Rasband at NIH, available by anonymous FTP at 128.231.98.32) was employed for image analysis (Figure 1 ). Assessment of cell proliferation was further assisted by macros written by one of us (J.I.S.) and described below.
In the gray scale digitized image captured with the red color channel the intensity of the red stained BrdU-containing nuclei was comparable with nonstained nuclei, such that all of the nuclei in the field were detected and counted. After editing the image to make any corrections that were needed to ensure that the computer representation of the field was accurate compared with the microscope image, a table containing the area, minimum axis and major axis for each nucleus in the field was generated. These data were copied into the spreadsheet program Excel®. This procedure was repeated on the same field using the blue color channel. In the gray scale digitized image captured with the blue color channel the intensity of the red stained nuclei was enhanced, while the blue stained nuclei were reduced such that they were effectively filtered out, facilitating discrimination of red staining nuclei (i.e. the BrdU-containing nuclei) by the density slice control.
For each liver section a minimum of 15 fields and 1300 nuclei were counted. Once all the field data were collected into Excel® the shape and size of each nucleus were calculated. Additionally, we discriminated among different hepatocyte populations; binucleated hepatocyte nuclei were defined as two hepatocyte nuclei in close proximity that appeared to be in the same cell and karyomegalocytes were defined as hepatocyte nuclei larger than the average hepatocyte nuclei plus one standard deviation. Nuclei were considered to have been derived from a hepatocyte if the area was <0.75 nm 2 and the roundness (roundness = minor axis/major axis) was >0.75 (30) . Nuclei were determined to have been derived from binucleated hepatocyte if the area was >0.75 p.m 2 and the roundness was <0.75. Nuclei were determined to have been derived from a karyomegalocyte if the area was >0.75 (irn 2 and the roundness was >0.75. Finally, nuclei were determined to have been derived from non-hepatocytes if the area was <0.75 |im 2 and the roundness was <0.75. One of the authors (J.I.S.) is a DVM pathologist and played a key role in establishing these parameters. The final step was to calculate the percent labeling index for both hepatocytes and non-hepatocytes. For this analysis 'hepatocytes' designated a user defined term that consisted of the sum of the number of hepatocyte nuclei, the number of karyomegalocyte nuclei and twice the number of binucleated hepatocyte nuclei. The percent labeling index was calculated as the number of labeled nuclei of a particular cell type (i.e. 'hepatocytes' or non-hepatocytes) divided by the total number of nuclei of that type, multiplied by 100.
Global liver DNA methylation analysis
Sssl methylase (CpG methylase) utilizes SAM to methylate the 5 position of C at every CpG site in DNA that is not methylated. In this manner we were able to assess the methylation status of liver DNA indirectly, as hypomethylation of DNA was apparent as an increase in incorporation of methyl groups. Global liver methylation analysis was carried out essentially as described (31). Briefly, 1 Jig DNA was incubated with 2 (xCi [ 3 H-methyl]Sadenosyl-L-methionine (New England Nuclear, Boston, MA; sp. act. 84.1 Ci/ mmol) and 3 U Sssl methylase (New England Biolabs, Beverly, MA) for 1 h at 30°C. All reactions were carried out in duplicate. Radiolabel incorporation into DNA was proportional to DNA concentration and linear during the period of measurement. Reactions were carried out a minimum of four times on each DNA sample and each sample was from a different animal (six animals per group). Results were calculated as c.p.m./|ig/h and expressed as a percentage of the averaged control values. 
Results
Cell proliferation
We have determined that in normal mouse liver 65-75% of the cells are hepatocytes and 25-35% are non-hepatocytes (data not shown), while only 2-4% of the hepatocytes and 11-15% of the non-hepatocytes are undergoing cell proliferation ( Figure 2) . The values we obtained for hepatocyte and nonhepatocyte populations in mouse liver are similar to those observed in the rat (32) . The level of basal hepatocyte proliferation is higher (P < 0.05) in C57BL/6 (average in controls 3.9%) as compared with B6C3F1 (average in controls 2.5%) (Figure 2 ). Administration of a CMD diet led to an increase in hepatocyte proliferation beginning after 1 week, but did not reach statistical significance until the second week of administration 15 Fig. 3 . Hepatocyte labeling index in B6C3F1 and C57BL/6 male mice after CMD diet administration for 1, 2 or 4 weeks and in the recovery group (4 weeks diet followed by 2 weeks of control diet). Hepatocyte DNA synthesis is measured as an indirect measure of cell proliferation via immunohistochemistry and a Macintosh-based image analysis system (NIH Image). 'Statistically significant difference from age-matched controls (P < 0.05) using a two-tailed Student's /-test n = 4-6. Error bars denote standard error of the mean.
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in both B6C3F1 and C57BL/6 ( Figure 3 ). The increase continued throughout the treatment period and returned to control values in the recovery groups. Notably, the increase in hepatocyte cell proliferation was larger in the relatively liver tumor-resistant C57BL/6. PB administration led to an increase in cell proliferation at the 1 week time point in both strains, with the increase being larger in C57BL/6 (Figure 4) . After 2 weeks PB C57BL/6 returned toward control values, while cell proliferation in B6C3F1 was still elevated above control values. By the 4 week time point the level of cell proliferation returned to control values in both strains.
Co-administration of a CMD diet and PB led to statistically significant increases in hepatocyte proliferation in both strains at all time points (excluding the recovery group). The CMD diet appears to overcome the inhibitory effects of PB at 4 weeks of administration, as evidenced by the increase in hepatocyte labeling over the PB group alone ( Figure 5 ).
Global methylation status
Global DNA hypomethylation was induced by the administration of a CMD diet in B6C3F1 and C57BL/6 mice and this occurred to a larger extent in the relatively susceptible B6C3F1 mouse ( Figure 6 ). Interestingly, DNA methylation status in the B6C3F1 mouse liver approached control values at the week 2 time point, before rebounding to a more hypomethylated state at the 4 week time point. In C57BL/6 mice the CMD diet led to a lower degree of hypomethylation at the week 1 and 4 time points, as compared with B6C3F1. The C57BL/6 mice also returned toward control levels of global methylation in the recovery group. After 12 weeks on the CMD diet striking increases in hypomethylation were evident in both mouse strains, with larger increases in C57BL/6 ( Figure 6 ). Therefore C57BL/6 is not completely resistant to alterations in methylation status.
PB led to a dramatic and consistent level of hypomethylation only in B6C3F1 mouse liver (Figure 7) . Importantly, 2 weeks on a control diet after 4 weeks of PB were able to restore, at least partially, the methylation status of B6C3F1 liver DNA (Figure 7 ). C57BL/6 mice were resistant to the effects of PB on global liver DNA methylation status (Figure 7) .
Co-administration of a CMD diet and PB led to enhanced hypomethylation in both strains over either treatment alone and again the animals were able to recover (Figure 8 ). The B6C3F1 mice appeared to partially restore their liver DNA methylation status after 2 weeks of co-administration of CMD
Weeki
Week 2 Week 4 Recovery Fig. 8 . Effect of the co-administration of a CMD diet and 0.05% (w/w) PB in the drinking water on the global methylation status of liver DNA in B6C3F1 and C57BL/6 male mice. Sssl methylase was used to assess DNA methylation status indirectly. The enzyme utilizes [ 3 H-methyl]SAM to donate a methyl group to the C of any unmethylated CpG sites. Thus hypomethylation is apparent as an increase in incorporation of methyl groups. *Statistically significant difference from controls (P < 0.05) using a two-tailed Student's r-test. n = 5-6. The control values±SEM are presented in the legend to Figure 6. diet and PB, similar to the effect evident with CMD diet alone (compare week 2 between Figures 6 and 8 ). This trend was not readily apparent in C57BL/6.
Discussion
The results of this report indicate a disconnection between non-genotoxic tumor promotion-induced cell proliferation and tumor sensitivity in mouse liver, as the relatively liver tumorresistant C57BL/6 had a higher level of cell proliferation induced by tumor promoter stimuli than the relatively sensitive B6C3F1. Importantly, global hypomethylation was evident to a larger extent in the liver tumor-sensitive B6C3F1. These results, taken together, illustrate that the relatively liver tumorresistant C57BL/6 retains the capacity to maintain the methylation status of DNA under conditions of promoter treatment and increased cell proliferation. Thus B6C3F1 appears to lack the capacity for and/or fidelity of maintenance methylation when exposed to known tumor promoting stimuli. Further, these data demonstrate that C57BL/6 is capable of exhibiting hypomethylation of liver DNA in response to a CMD diet or a CMD diet co-administered with PB. Thus, in this respect, there is a quantitative, not a qualitative, difference between B6C3F1 and C57BL/6 mice following treatment with tumor promoters.
There have been a few reports characterizing basal liver cell proliferation in relatively liver tumor-sensitive versus relatively liver tumor-resistant strains of mice. Generally the sensitive strains have been reported to have higher basal cell proliferation than the resistant strains (25, 33) . In both of these studies, however, cell proliferation was assessed indirectly by determining [ 3 H]thymidine incorporation into liver DNA/(ig DNA. In the present study we utilized BrdU-containing minipumps and demonstrated that C57BL/6 had a higher level of basal liver cell proliferation (both in hepatocytes and nonhepatocytes) than B6C3F1 (Figure 2 ). One advantage of our methodology, in a relatively quiescent organ like the liver, is the cumulative assessment of DNA synthesis over 7 days, providing a more sensitive indication of the extent of cell proliferation as compared with one (25) 
A second advantage of our image analysis-based approach is the ability to discern changes in particular cell populations in the liver. We distinguish between hepatocyte and nonhepatocyte cell proliferation. The basal level of cell proliferation is higher in non-hepatocytes as compared with hepatocytes in C57BL/6 and B6C3F1 mice (Figure 2 ). This distinction may bias results when cell proliferation determinations are based upon total amounts of [ 3 H]thymidine/|Xg DNA. Treatment related effects on non-hepatocyte cell proliferation were not remarkable (data not shown).
It seems likely to us that there may be different basal levels of apoptosis in C57BL/6 and B6C3F1 mice, as the basal level of cell proliferation of hepatocytes and non-hepatocytes is greater in C57BL/6 (Figure 2) . Thus a higher level of cell death would be required in C57BL/6 to maintain normal liver size. A heightened level of apoptosis occurring in the liver of C57BL/6 could more efficiently remove initiated cells (referenced in 34). Interestingly, PB, which leads to liver tumors in B6C3F1 after 12 months, but not C57BL/6 mice after 18 months (20), did not lead to global hypomethylation in the relatively resistant C57BL/6. Along these lines, C57BL/ 6 animals that received PB for 4 weeks followed by control drinking water for 2 weeks (i.e. the recovery group) exhibited less hepatocyte cell proliferation than the animals that received control diet for the entire 6 weeks (P < 0.05). This could be explained by apoptosis occurring to a greater extent in C57BL/ 6 than in B6C3F1.
Cells capable of forming tumors after chronic PB treatment appear to have overcome the growth inhibitory effects of PB (27, 35, 36) . This is consistent with what we have observed. PB does not merely promote spontaneous tumor formation in the mouse, as PB-induced tumors have unique characteristics compared with spontaneous liver tumors (37, 38) . A decrease in epidermal growth factor receptors (39) plus an increase in the level of transforming growth factor P (TGFP) (40) , TGFP receptors (35) and M6P-IGF2r, involved in activating TGFfj (36) , in normal hepatocytes are associated with chronic PB administration. This would be expected to inhibit hepatocyte proliferation. However, M6P-IGF2r and TGFP are decreased in PB-promoted preneoplastic lesions (36) and TGFP is decreased in PB-promoted liver tumors (35) . Additionally, hypomethylation of DNA at early times after PB administration may facilitate resistance to PB inhibition of proliferation by causing increased expression of raf and Ha-ras, which can decrease the ability of TGFP to inhibit proliferation of hepatocytes (38) . Furthermore, in the light of its role in activating TGFP, the M6P-IGF2r gene can be viewed as a tumor suppressor gene (36, 41) . The M6P-IGF2r gene is imprinted in the mouse, while both alleles are usually expressed in the human. This could, in part, provide a basis for the observations that mice (especially those strains that have a relatively low capacity to maintain nascent methylation patterns, e.g. B6C3F1) are more susceptible to liver cancer than humans (referenced in 42, 43) .
PB administered with a choline-devoid diet inhibited the level of cell proliferation compared with CMD diet alone after 1 and 3 weeks of treatment (13) . In contrast, we have demonstrated that the CMD diet appears to overcome the mitoinhibitory effect of PB after 1,2 and 4 weeks of administration ( Figure 5 ). Thus cells undergoing DNA synthesis in response to a CMD diet co-administered with PB may be the progenitors of eventual tumor formation. A higher level of apoptosis of initiated cells in the relatively liver tumor-resistant C57BL/6 may lead to regenerative hyperplasia and thus explain the higher level of cell proliferation exhibited by C57BL/6.
To further compare our data with literature values reported for the rat, the level of hepatocyte synthesis in the rat is higher after 1 week of CMD diet than after 3 weeks (13), while C57BL/6 and B6C3F1 mice have the highest level of cell proliferation after 4 weeks of CMD diet administration (Figure 3) . In both mouse strains cell proliferation increased throughout the study in response to the CMD diet, returning toward control values in the recovery groups. Thus it appears rats and mice respond differently to CMD diet-induced cell proliferation.
The hypomethylation observed in the current studies cannot be accounted for fully on the basis of decreased maintenance methylation during periods of increased cell proliferation. Therefore, it is possible that some demethylation is occurring that is not linked to DNA replication. A decrease in DNA 5MeC may be brought about by an enzymatic process involving replacement of 5MeC by C (44, 45) . The key observation in the present report is that the B6C3F1 mouse is less capable of maintaining its normal level of methylation than the C57BL/ 6 strain in response to treatment with PB and/or a CMD diet, two promoters of liver tumorigenesis.
Alterations to the genome (e.g. point mutation, chromosome loss and changes in methylation status) occur at multiple points in the carcinogenic process (46, 47) . Indeed, alterations in methylation may play a variety of roles in carcinogenesis (6) . In addition to enhancing our understanding of the transformation process, research in the area of DNA methylation is providing the type of information which is required to take a more rational approach to risk assessment (48) .
An assessment of DNA methylation status should be considered for inclusion as an ancillary component (e.g. in addition to routine histopathology, assessments of cell proliferation in vivo and in vitro tests for the potential to cause genotoxicity) of both subchronic studies and carcinogen bioassay (7, 49) . This could aid in discerning the mechanism of action (e.g. a possible non-genotoxic, threshold-exhibiting mechanism) of the chemical being evaluated. In addition, this information could facilitate a rational approach to dose setting and the selection of appropriate doses for risk assessment, e.g. if toxicity occurs only at doses above that which cause hypomethylation in the target organ(s). These data could aid in providing the basis for placing a proper emphasis on lower doses. Dose influences mechanism and, over a wide range of doses, mechanism changes with dose (50) . Doses of the test chemical that cause alterations in DNA methylation should be viewed as having compromised a key homeostatic mechanism, e.g. a threshold that has been exceeded, and be deemed excessive. However, it would not be appropriate to consider measurement of alterations in DNA methylation as a shortterm test for carcinogens.
The data in this current report, in conjunction with our previous investigation (38) , lead us to propose that the B6C3F1 mouse has a decreased capacity for and/or fidelity of maintaining nascent DNA methylation and this defect explains, in part, the relatively high sensitivity of this animal to both spontaneous and chemically-induced liver tumors as compared with the relatively resistant C57BL/6 strain. This should be viewed within the context that: (i) the overall level of genomic 5MeC appears to be maintained more effectively in human 1256 cells as compared with rodent cells (51; referenced in 42); (ii) there are differences between the mouse and human with regard to both methylation status and base sequence (52) in the 5' flanking region of Ha-ras, an oncogene that is frequently involved in mouse liver tumors (53) , while it only very rarely plays a role in human cancer (54) . Therefore, it appears to be inappropriate to make human risk assessment decisions based only upon a liver tumor response in the B6C3F1 mouse. In those situations where the results of a bioassay indicate that the mouse liver is one of several sites where an increased tumor incidence occurs the mouse liver tumor response should be evaluated with regard to the mode of action of the chemical in question. Safety assessment for those chemicals acting through a threshold-exhibiting mode of action should be based on a safety factor (or multiplicity of exposure) approach (50) .
